The clincher: Once a prototypedrug works against one kinase, Vertex figures it can easily tweak the compound to inhibit other siblings in the kinase family--and then attack other protein groups, as well.
Last week, Russell and Damiano visited the Food and Drug Administration offices in Silver Spring, Maryland, to show regulators a prototype for the artificial pancreas.